<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page3_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page3_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>23</o:Revision>
  <o:TotalTime>135</o:TotalTime>
  <o:Created>2006-11-01T12:44:00Z</o:Created>
  <o:LastSaved>2006-11-03T14:43:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>608</o:Words>
  <o:Characters>3466</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>28</o:Lines>
  <o:Paragraphs>6</o:Paragraphs>
  <o:CharactersWithSpaces>4256</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	mso-font-kerning:16.0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	font-style:italic;}
h4
	{mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:maroon;
	font-weight:normal;
	font-style:italic;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
@list l0
	{mso-list-id:498231737;
	mso-list-type:hybrid;
	mso-list-template-ids:1727273840 1696212148 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:46.35pt;
	mso-level-number-position:left;
	margin-left:46.2pt;
	text-indent:-17.85pt;
	mso-ansi-font-size:8.0pt;
	font-family:Symbol;}
@list l1
	{mso-list-id:1831363692;
	mso-list-type:hybrid;
	mso-list-template-ids:-1058622560 1696212148 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:46.35pt;
	mso-level-number-position:left;
	margin-left:46.2pt;
	text-indent:-17.85pt;
	mso-ansi-font-size:8.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1029"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:139.5pt;
 height:45pt'>
 <v:imagedata src="./Page3_files/image001.png" o:title="InterPro"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=186 height=60
src="./Page3_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:maroon'>Fibrinogen<o:p></o:p></span></h1>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></h1>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'>Fibrin
and Cancer<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Malignant
tumours can initiate inflammation, with fibrinogen forming part of the tumour
inflammatory response.<span style="mso-spacerun: yes">  </span>Fibrinogen that
is localised to tumours appears to be converted to fibrin polymers, possibly as
a result of the inflammatory response by leukocytes that accumulate and
infiltrate the tumour mass.<span style="mso-spacerun: yes">  </span>The fibrin
polymers appear to accumulate within the tumour stroma and to envelop the
tumour cells, possibly by binding to the integrin-like receptors on the tumour
cell surface.<span style="mso-spacerun: yes">  </span>The fibrin matrix may
help promote angiogenesis within the tumour, which is necessary for its growth
and propagation.<span style="mso-spacerun: yes">  </span>This process may occur
because of fibrin’s role in inflammation.</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'>Atherosclerosis<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Atherosclerosis
is the clogging, narrowing and hardening of the arteries, which can lead to
stroke, heart attack, eye problems and kidney problems.<span
style="mso-spacerun: yes">  </span>Atherosclerosis is characterised by the
deposition of plaques, which consist of hydrophobic lipids, macrophages, smooth
muscle cells and proteins beneath the endothelial lining of large arteries.<span
style="mso-spacerun: yes">  </span>Plaques also appear to contain fibrin and
its degradation products, which may be involved in the growth and development
of plaques, possibly through its role in inflammation.<span
style="mso-spacerun: yes">  </span>As a result, high levels of blood fibrinogen
may be a risk factor for atherosclerosis.<span style="mso-spacerun: yes"> 
</span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'>Dysfibrogenaemia<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Mutational
changes in any of the three genes (FGA, FGB, and FGG) that encode the three
fibrinogen polypeptides (A<span style='font-family:Symbol'>a</span>, B<span
style='font-family:Symbol'>b</span> and <span style='font-family:Symbol'>g</span>)
can result in structural changes in fibrinogen that can affect its properties,
such as its ability to form clots.<span style="mso-spacerun: yes">  </span>The
general term, <a
href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=134820"
title="OMIM link for dysfibrogenaemia">dysfibrinogenaemia</a>, relates to
congenital defects in the fibrinogen molecule that lead to recurrent thrombosis.
Patients with dysfibrogenaemia can show prolonged clot formation, or, in the
most sever cases, no clot formation at all.<span style="mso-spacerun: yes"> 
</span>Dysfibrinogenaemia can lead to abnormal clotting, increased bleeding and
wound splitting.<span style="mso-spacerun: yes">  </span>Defects can occur in
the conversion of fibrinogen to fibrin, though in the majority of cases,
defects occur in the aggregation of fibrin into a polymer clot.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'>Fibrinogen
binding by Pathogens<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>The
pathogenic bacteria <i>Streptococcus agalactiae</i> is responsible for causing pneumonia,
sepsis, and<sup> </sup>meningitis in newborns, as well as cellulitis,<sup> </sup>arthritis,
urinary tract infections, and endocarditis in immune-compromised adults.<span
style="mso-spacerun: yes">  </span>These bacteria carry a receptor, FbsA, which
is capable of binding to fibrinogen.<span style="mso-spacerun: yes"> 
</span>This binding results in the fibrinogen-dependent aggregation of
platelets, permitting the bacteria to adhere to the extracellular matrix and
invade the pulmonary epithelium, which is thought to be necessary for
infection.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'>Snake
Bites, Fibrinolysis and Clinical Drugs<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Several
different snake species, including <i>Viperidae</i> (vipers and rattlesnakes)
and <i>Elapidae</i> (cobras, kraits and coral snakes), can produce venoms
containing fibrin(ogen)olytic enzymes.<span style="mso-spacerun: yes"> 
</span>These enzymes attack fibrin to degrade blood clots, as well as
fibrinogen to prevent further clot formation.<span style="mso-spacerun: yes"> 
</span>Some of these enzymes can also attack basement membrane proteins to
induce haemorrhaging.<span style="mso-spacerun: yes">  </span>There are
different types of fibrin(ogen)olytic enzymes, some attacking a specific chain,
such as <span style='font-family:Symbol'>a</span>-fibrin(ogen)ase and <span
style='font-family:Symbol'>b</span>-fibrin(ogen)ase, which preferentially
attack the A<span style='font-family:Symbol'>a</span> or B<span
style='font-family:Symbol'>b</span> polypeptide of fibrin(ogen, respectively.<span
style="mso-spacerun: yes">  </span>Two general classes of fibrinolytic enzymes
have been characterised, metalloproteinases and serine proteinases, which
differ in their mechanism of action.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Snake
venom fibrinolytic enzymes have potential use as clinical drugs for the treatment
of occlusive thrombi - for example, <i><span style='color:maroon'>fibrolase</span></i>,
a fibrinolytic metalloproteinase from <i>Agkistrodon contortrix contortrix</i>,
and the <i><span style='color:maroon'>serine</span></i> <i><span
style='font-family:Symbol;color:maroon'>b</span><span style='color:maroon'>-fibrinogenolytic
proteinase</span></i> from <i>Vipera lebetina</i>.<span style="mso-spacerun:
yes">  </span>Recombinant enzymes have also been produced for clinical trials,
such as alfimeprase, a structurally altered fibrolase.</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Next:<span style="mso-spacerun:
yes">  </span><a href="Page4.htm" title="Page 3">What InterPro Tells Us</a><o:p></o:p></span></h2>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Previous:<span
style="mso-spacerun: yes">  </span><a href="Page2.htm" title="Page 1">Wound
Healing</a></span><span style='font-style:normal'><o:p></o:p></span></h2>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
